The prefilled syringe drug molecule market has seen significant evolution as healthcare systems globally strive for safer, more efficient drug delivery methods. Prefilled syringes offer an innovative ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

Halozyme Therapeutics, Inc. (Halozyme) announced that argenx has received US Food and Drug Administration (FDA) approval of Vyvgart Hytrulo prefilled syringe for self-injection (efgartigimod alfa and ...

Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional.

FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options.

VYVGART Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients are able to self ...

The approval of VYVGART Hytrulo prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to VYVGART Hytrulo in a vial.

VYVGART Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients are able to self ...

VYVGART Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional.

The global prefilled syringes market share is projected to grow from US$ 6.69 Billion in 2022 to US$ 15.0 Billion by 2030, driven by the increasing prevalence of chronic diseases and rising demand ...

The FDA has approved Purified Cortrophin Gel (repository corticotropin injection USP) in a prefilled syringe presentation.